R
Rahul Jain
Researcher at National Institutes of Health
Publications - 119
Citations - 3726
Rahul Jain is an academic researcher from National Institutes of Health. The author has contributed to research in topics: Catalysis & Alkylation. The author has an hindex of 30, co-authored 105 publications receiving 3207 citations. Previous affiliations of Rahul Jain include Tulane University & University of Louisville.
Papers
More filters
Journal ArticleDOI
Quinolines and structurally related heterocycles as antimalarials
TL;DR: This review provides a comprehensive literature compilation concerning the study of quinolines and also other heterocycles structurally similar to quinoline scaffold in the treatment of malaria.
Journal ArticleDOI
Antimalarials from nature
TL;DR: Recent advances in antimalarial drug discovery from natural sources are presented, including plant extracts, and compounds isolated from plants, bacteria, fungi and marine organisms, which offer new and novel scaffolds for development as antimalarials.
Journal ArticleDOI
Recent advances in new structural classes of anti-tuberculosis agents.
Amit Nayyar,Rahul Jain +1 more
TL;DR: This review provides a comprehensive literature compilation on advances in the new structural classes of anti-TB analogs reported during the past five years and discusses and observations are concentrated on chemotherapeutic potential of alphabetically listed twenty-seven newStructural classes ofAnti-tuberculosis agents.
Journal ArticleDOI
Synthesis, anti-tuberculosis activity, and 3D-QSAR study of 4-(adamantan-1-yl)-2-substituted quinolines.
TL;DR: A 3D-QSAR analysis of AQCH by its reaction with various aliphatic, aromatic, and heteroaromatic aldehydes led to the synthesis of 4-adamantan-1-yl-quinoline-2-carboxylic acid alkylidene hydrazides (Series 2), which have produced promising antimycobacterial activities.
Journal ArticleDOI
Ring-substituted quinolines as potential anti-tuberculosis agents.
TL;DR: In vitro antimycobacterial properties of ring-substituted quinolines constituting 56 analogues against drug-sensitive and drug-resistant M. tuberculosis H37Rv strains are reported, comparable to first line anti-tuberculosis drug, isoniazid.